Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Solban

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Cancer Research|June 3, 2006
Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancerNicolas Solban, Pål K Selbo, Selbo K Pål, et al.
The Journal of Biological Chemistry|July 9, 2011
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growthRoselyne Castonguay, Eric D Werner, Robert G Matthews, et al.
Molecular Cancer Therapeutics|February 4, 2010
ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growthDianne Mitchell, Eileen G Pobre, Aaron W Mulivor, et al.
Oncotarget|June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinomaXiaoen Wang, Nicolas Solban, Prateek Khanna, et al.
Journal of Medicinal Chemistry|September 5, 2024
Discovery and Evaluation of TLR-Targeted Immune AgonistsNatalia Chernyak, Bhagyashree Bhagwat, Saraswathi Naravula, et al.
Toxicology and Applied Pharmacology|September 2, 2020
Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout miceAmy G Aslamkhan, Qiuwei Xu, Amy Loughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2012
A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strengthMarc Baud'huin, Nicolas Solban, Milton Cornwall-Brady, et al.
Biochemistry and Biophysics Reports|April 20, 2026
Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modelingAlireza Savadipour, Krishna S Tummala, Eric S Muise, et al.
ACS Medicinal Chemistry Letters|September 17, 2021
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 InhibitorsBrett Hopkins, Hongjun Zhang, Indu Bharathan, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) InhibitorsQinglin Pu, Hongjun Zhang, Liangqin Guo, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Cancer Research|June 3, 2006
Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancerNicolas Solban, Pål K Selbo, Selbo K Pål, et al.
The Journal of Biological Chemistry|July 9, 2011
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growthRoselyne Castonguay, Eric D Werner, Robert G Matthews, et al.
Molecular Cancer Therapeutics|February 4, 2010
ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growthDianne Mitchell, Eileen G Pobre, Aaron W Mulivor, et al.
Oncotarget|June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinomaXiaoen Wang, Nicolas Solban, Prateek Khanna, et al.
Journal of Medicinal Chemistry|September 5, 2024
Discovery and Evaluation of TLR-Targeted Immune AgonistsNatalia Chernyak, Bhagyashree Bhagwat, Saraswathi Naravula, et al.
Toxicology and Applied Pharmacology|September 2, 2020
Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout miceAmy G Aslamkhan, Qiuwei Xu, Amy Loughlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2012
A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strengthMarc Baud'huin, Nicolas Solban, Milton Cornwall-Brady, et al.
Biochemistry and Biophysics Reports|April 20, 2026
Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modelingAlireza Savadipour, Krishna S Tummala, Eric S Muise, et al.
ACS Medicinal Chemistry Letters|September 17, 2021
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 InhibitorsBrett Hopkins, Hongjun Zhang, Indu Bharathan, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) InhibitorsQinglin Pu, Hongjun Zhang, Liangqin Guo, et al.
Pageof 3